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We congratulate Gomez et al1 for their very important contribution 
on the patterns of failure, toxicity, and 
survival after extrapleural pneumonec-
tomy and hemithoracic intensity-mod-
ulated radiation therapy, for malignant 
pleural mesothelioma. Studies about 
patterns of failure are of great impor-
tance because patterns of local and dis-
tant failure might be the most important 
test of adequate treatment planning and 
treatment success.2
After extrapleural pneumonec-
tomy and hemithoracic intensity-mod-
ulated radiation therapy, only 16% of 
the patients experienced local recur-
rence, whereas, distant recurrence was 
observed in 59% of the patients. If we 
go into details, the predominant site 
of distant recurrence was contralat-
eral hemithorax in the majority of the 
patients (41%; n = 35) followed by 
abdomen and pelvis, including liver in 
28% of the patients (n = 24).
In general, distant recurrence 
is defined as tumor that has spread to 
organs or tissues distant from the pri-
mary tumor. However, contralateral 
hemithorax and abdomen are located 
directly at the resection borders. 
Contralateral pleura and peritoneum 
could be opened accidentally during 
extrapleural dissection in the anterior or 
posterior mediastinum and diaphragmal 
resection. Tumor cell dislocation might 
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occur at these resection borders. The 
resection borders are not far away from 
the primary tumor site. It is question-
able whether these kind of recurrences 
might be hematogenous spread. Thus, 
the question arises whether recurrence 
at the resection borders in terms of con-
tralateral hemithorax or abdomen and 
pelvis should be (still) considered as 
local recurrence or distant recurrence 
for malignant pleural mesothelioma?
REFERENCES
 1. Gomez DR, Hong DS, Allen PK, et al. 
Patterns of failure, toxicity, and survival after 
extrapleural pneumonectomy and hemitho-
racic intensity-modulated radiation therapy 
for malignant pleural mesothelioma. J Thorac 
Oncol 2013;8:238–245.
 2. Berthelsen AK, Dobbs J, Kjellén E, et al. What’s 
new in target volume definition for radiologists 
in ICRU Report 71? How can the ICRU vol-
ume definitions be integrated in clinical prac-
tice? Cancer Imaging 2007;7:104–116.
Copyright © 2013 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/12/87-00
Disclosure: The authors declare no conflict of 
interest.
Address for correspondence: Daniel Gomez, MD, 
University of Texas, MD Anderson Cancer 
Center, 1840 Old Spanish Trail, Houston, TX 
77054. E-mail: dgomez@mdanderson.org
In Response:
We thank Drs. Bolukbas, Eberlein, 
and Schirren for their letter and their 
inquiry regarding patterns of recurrence 
for malignant pleural mesothelioma at 
the resection borders. We do concur that 
the classification of recurrence in this 
setting requires special consideration, 
because of the unique components of 
an extrapleural pneumonectomy. And 
indeed, it can be difficult to distinguish 
between microscopic residual disease 
that has occurred at the surgical/radia-
tion field margin versus tumor spread 
hematogenously to the contralateral 
hemithorax or abdomen. Unfortunately, 
there is no way to determine with abso-
lute certainty the process underlying 
these recurrences, particularly with 
the additional concern that has been 
previously published of tumor seeding 
through biopsy or surgery.1,2 Therefore, 
much of the categorization for reporting 
purposes relies on clinical judgment.
In the vast majority of cases that 
we have classified as being distant recur-
rences, the tumors have been located at 
sites not in direct continuity with the 
postpneumonectomy space. Most con-
tralateral lung recurrences in this series 
were intraparenchymal tumor nodules, 
not pleural-based recurrences and are 
most probably related to hematogenous 
spread. Similarly, liver recurrences were 
exclusively intraparenchymal. One cer-
tainly could argue (as has been done in 
the past by others) that intra-abdominal 
recurrences are secondary to seeding at 
the time of surgery and should be clas-
sified as “local” recurrences. However, 
a significant number of patients will 
have occult carcinomatosis before sur-
gery, so transdiaphragmatic spread to 
the abdominal cavity (either by direct 
invasion or, more likely by lymphatog-
enous spread) is a common feature of 
this disease even without violation 
of the diaphragm during extrapleural 
pneumonectomy. It is therefore not sur-
prising that abdominal recurrences are 
observed after cytoreductive surgery.
At our institution, we classify 
recurrence of disease that occurs in a 
region that is clearly in the resection 
bed or at the resection margin above 
the diaphragm, or in the mediastinal 
lymph nodes, as local–regional recur-
rence. In contrast, disease that is evi-
dently removed from the ipsilateral 
hemithorax or is below the diaphragm, 
including contralateral lung nodules, 
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of therapy (WBRT, systemic, and 
intra-CSF chemotherapy), a therapeu-
tic strategy, which the authors con-
clude, results in best outcomes.
The study was unclear as to how 
determinations of CSF abnormalities 
were made (dichotomous or continu-
ous variable), which according to the 
authors contention, impact survival 
independent of treatment. Nonspecific 
CSF abnormalities likely reflect CNS 
tumor burden more closely correlated 
with magnetic resonance imaging–
defined disease. The authors posit that 
ventriculo-peritoneal shunting is asso-
ciated with improved survival, which 
seems counterintuitive because such 
patients by definition are poor can-
didates for intra-CSF chemotherapy 
because of CSF compartmentalization. 
WBRT in isolation has been shown to 
be of limited benefit in patients with 
NSCLC and LM.5 LM is a neuraxis dis-
ease, with CSF dynamically circulating 
through brain and spine compartments. 
Consequently, it is not surprising that 
treatment of only a single CSF com-
partment with WBRT does not impact 
survival.
The statement that intra-CSF 
chemotherapy, WBRT, and epidermal 
growth factor receptor inhibitors, but 
not cytotoxic chemotherapy, with recog-
nized limited CNS penetration improves 
survival in patients with NSCLC and 
LM seems overreaching, given the chal-
lenges of a retrospective study and lack 
of appropriate controls, which necessar-
ily results in treatment-selection bias. 
As the authors indicate, management of 
solid tumor-related LM remains chal-
lenging because of a paucity of prospec-
tive trials and consequently the lack of 
standardization in LM-related treatment 
that is evidenced based.
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patients with LM defined by positive 
cerebrospinal fluid (CSF) cytology 
were included. Consequently, the study 
cohort was heterogenous with respect to 
identified LM-prognostic features (the 
presence or absence of radiographic 
bulky disease, carcinomatous encepha-
lopathy, performance status, CSF flow 
disruption, and burden of systemic 
disease), and therefore, it was unclear 
how many patients could be considered 
as favorable risk and LM-treatment 
appropriate.2,3 Strikingly different than 
the literature, the current study had a 
high incidence of LM at diagnosis of 
NSCLC (17%), a near-uniform concor-
dance of positive CSF cytology (100%) 
and magnetic resonance imaging find-
ings consistent with LM (94%), a high 
incidence of hydrocephalus (17%), lack 
of spine LM-related disease, and a high 
incidence of brain metastasis (66%).4
Because of the retrospective 
nature of the study, there were no a 
priori determinants of treatment such 
that treatment was defined individu-
ally, without apparent standardization 
making cross-comparisons between 
treatment groups problematic. There 
was no characterization before 
intra-CSF chemotherapy of whether 
patients underwent radioisotope CSF 
flow studies, to determine CSF com-
partmentalization because of LM that 
would compromise intra-CSF drug 
distribution. Although 66% of all the 
patients manifested brain metasta-
sis, only 32% received whole-brain 
radiotherapy (WBRT). Furthermore, 
there was no mention of administer-
ing spine radiotherapy for symptom-
atic or radiographically bulky disease 
in spine. Table 3 suggests that 13% of 
patients received supportive care (no 
explanation as to why), 12% were not 
treated with intra-CSF chemotherapy 
(again no explanation as to why), and 
only 12% received all three modalities 
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Lee et al.1 are to be congratulated for their analysis of patients with 
non–small-cell lung cancer (NSCLC) 
and leptomeningeal metastases (LM). 
Several aspects regarding the study 
warrant commentary.
First, this was a single-institu-
tion retrospective study, in which all 
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abdominopelvic or peritoneal dis-
ease, and contralateral pleural disease, 
is classified as a distant recurrence. 
The aims of this classification are not 
only to convey the mechanism of pro-
gression but also to clarify options 
for salvage therapy. Further studies 
comparing outcomes in patients with 
marginal recurrences versus removed 
distant metastases will provide further 
enlightenment regarding the optimal 
manner in which to allocate and treat 
this distinct group of patients.
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